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survival after HT have been described. However, whether there are signiﬁcant racial/ethnic differences in PRA
among adults awaiting HT is poorly characterized.Methods We identiﬁed patients age 18 years in the Organ Procurement and Transplantation database with race/ethnicity of
white, black, Hispanic, or Asian and listed for HT between 2000 and 2012 (N ¼ 19,704). A PRA value of 10% was
used to deﬁne clinically meaningful sensitization.Results Blacks had a higher peak PRA than did all other groups and were more likely to be sensitized. Black HT recipients
were more likely to experience graft failure than were Hispanic, white, and Asian recipients (31% vs. 27%, 26%, and
21%, respectively; p < 0.001). The median follow-up was 1,207 days (interquartile range: 373 to 2,364 days), with
a trend toward a shorter median time to graft failure in the Asian group than in the black, Hispanic, and white groups
(p ¼ 0.065). Sensitized blacks had the lowest rate of allograft survival, whereas nonsensitized Asians had the
highest survival. Using Cox proportional regression to adjust for other clinical variables, black race (HR: 1.3; 95%
conﬁdence interval [CI]: 1.2 to 1.5), Hispanic ethnicity (HR: 1.2; 95% CI: 1.0 to 1.5), and sensitization (HR: 1.2; 95%
CI: 1.1 to 1.4) remained predictors of higher rates of graft failure.Conclusions Race/ethnicity and level of sensitization are important predictors of graft survival. (J Am Coll Cardiol
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orthotopic heart transplantation (HT), disparities based on
race and socioeconomic status (SES) persist. Racial/ethnic
differences in long-term survival after HT are well recog-
nized, with several studies demonstrating shorter graft and
patient survival in HT recipients who are of racial/ethnic
minority background (1–3). The exact mechanisms for these
disparities are unclear; however, suggested explanations
include SES factors and biological and immunologic
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however, immunologic factors are likely to play an important
role. For example, the impact of human leukocyte antigen
(HLA) matching is disputed in cardiac allograft allocation;
however, recipients of racial/ethnic minority background
are more likely to have donor–recipientHLAmismatch (5) and
are more likely to have an episode of rejection during the ﬁrst
year after transplantation (6). These differences may inﬂuence
the observed racial disparities in post-transplantation outcomes,
although this has not yet been convincingly demonstrated.See page 2316Panel reactive antibody (PRA) screening is used among
patients being evaluated for HT to determine the presence
of circulating antibodies to known HLA antigens in
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2309a suitable donor, and to mitigate the risk for post-
transplantation antibody-mediated rejection. The higher the
PRA value, the greater the likelihood of a positive cross-match
with a random donor, and the lower the likelihood of receiving
a compatible transplant (7). Patients with higher PRA values
tend to have extended waiting times while listed for solid-organ
transplantation and lower rates of transplantation, although the
use of solid-phase PRA assays has inﬂuenced these factors
tremendously. At this time, the effect of race/ethnicity on
clinically signiﬁcant sensitization and its impact on post-
transplantation outcomes remain unclear, so we sought to
investigate wait-list characteristics and graft survival as func-
tions of race/ethnicity and PRA.Methods
Study population. All patients age 18 years of age who
were listed for a primary HT in the United States between
January 2000 and September 2012 were identiﬁed in
the Organ Procurement and Transplantation Network
(OPTN) database. The OPTN database includes data on
all patients listed for a HT in the United States, as
submitted by their transplantation centers. These data
were provided to the investigators as de-identiﬁed data.
The Health Resources and Services Administration and the
U.S. Department of Health and Human Services provide
oversight into the activities of the OPTN contractor, the
United Network of Organ Sharing. Formal review was
deemed unnecessary by the institutional review board at
Emory University, Atlanta, Georgia.
Study design and deﬁnitions. We compared baseline
characteristics and outcomes between white, black, His-
panic, and Asian patients listed for a primary HT during the
study period. We excluded patients who were listed for a
repeat HT or for multiorgan transplantation, and those
who had missing values for PRA. The primary endpoint
was graft failure in those patients who received a HT. Graft
failure was chosen as the primary endpoint instead of
patient survival because it allowed the inclusion of patients
who had died, had received repeat transplantation, or did
not have further information regarding their outcome of
graft failure. Other clinical endpoints analyzed included
time on the waiting list and risk for rejection in the ﬁrst
year after transplantation as functions of race, PRA, and
HLA mismatch. Patients who received a HT were followed
up until hospital discharge, death, or the day of last obser-
vation, with follow-up through September 2012.
Demographic and clinical variables were deﬁned at the
time of listing (for wait-list outcomes) and at the time of
transplantation (for post-transplantation outcomes). Race
was reported by the transplantation centers as one of the
following: white, black, Hispanic/Latino, Asian, American
Indian/Alaska Native, Native Hawaiian/Paciﬁc Islander,
multiracial, and other. Ethnicity was reported as Hispanic or
non-Hispanic. For all Hispanic patients in the study, race
and ethnicity variables were identical; therefore, all whitepatients in this analysis were
non-Hispanic white, and all
black patients were non-Hispanic
black. Because of the small sample
size of minority patients with
race/ethnicity other than black,
Hispanic, or Asian (<1% of the
sample), these patients were
excluded from this analysis.
PRA was analyzed as: 1)
a continuous variable based on
both the most recent value and
the peak value; and 2) a categorical variable in which most
recent PRA or peak PRA of 10% was considered sensi-
tized. HLA matching was analyzed as: 1) a continuous
variable on the basis of the number of mismatches; and 2) as
a categorical variable based on a value greater than or equal
to the median number of mismatches.
Clinical variables assessed for which none of the patients
had missing data included: age, sex, blood type, body mass
index (BMI), history of diabetes, renal function, wait-list
status (transplantation, death, or removal from the wait-
list), hemodynamic support (intra-aortic balloon pump,
temporary or durable mechanical support), mean pulmonary
artery pressure and pulmonary capillary wedge pressure, type
of medical insurance, level of education, and donor age.
Other clinical variables assessed included number of prior
pregnancies, prior blood transfusion (dichotomized), and
allograft ischemic time.
Statistical analysis. Data are presented as median (inter-
quartile range [IQR]) or as n (%) of patients. Baseline
characteristics were compared between racial/ethnic groups
using the chi-square test for categorical variables and the
Kruskal-Wallis test for continuous variables. Univariate
and multivariate Cox proportional hazards models were
developed using a forward-selection procedure, retaining
variables signiﬁcant at the 0.20 level, on the basis of
a likelihood ratio test; all variables in Table 1 were consid-
ered. Finally, we assessed the association of race/ethnicity
with the primary endpoint to evaluate the consistency of this
relationship and to assess the interaction of race/ethnicity
with other variables.
Data were analyzed with the use of SAS version 9.3 (SAS
Institute Inc., Cary, North Carolina).Results
Study population. During the study period, 33,037 U.S.
patients 18 years of age were listed for a primary HT. Of
these, 13,126 patients had missing PRA values and so were
excluded from the analysis. An additional 207 patients were
excluded for race/ethnicity other than white, black,
Hispanic, or Asian. The remaining 19,704 patients formed
the analytic cohort for this study.
Table 1 summarizes the baseline characteristics of the
study population. Black recipients were younger and had
Table 1
Baseline Characteristics of White, Black, Hispanic, and Asian Patients Listed for HT From
2000 to 2012
Characteristic
White
(n ¼ 14,269)
Black
(n ¼ 3,474)
Hispanic
(n ¼ 1,461)
Asian
(n ¼ 500) p Value
Age, yrs 56 (48–62) 49 (39–57) 51 (41–59) 53 (43–60) <0.001
Age group <0.001
18–39 yrs 1,881 (13) 911 (26) 327 (22) 103 (21)
40–59 yrs 7,510 (53) 1,946 (56) 808 (55) 266 (53)
60–69 yrs 4,613 (32) 591 (17) 311 (21) 124 (25)
70þ yrs 265 (2) 26 (0.7) 15 (1) 7 (1)
Male 11,147 (78) 2281 (66) 1087 (74) 392 (78) <0.001
Blood type <0.001
A 6,592 (46) 1,031 (30) 528 (36) 158 (32)
B 1,723 (12) 790 (23) 171 (12) 143 (29)
O 5,193 (36) 1,438 (41) 714 (49) 164 (33)
AB 761 (5) 215 (6) 48 (3) 35 (7)
BMI, kg/m2 27 (23–30) 27 (23–31) 26 (23–29) 23 (21–26) <0.001
BMI stratum <0.001
<25 kg/m2 5,291 (37) 1,315 (38) 609 (42) 339 (68)
25–29 kg/m2 5,426 (38) 1,173 (34) 527 (36) 119 (24)
30–35 kg/m2 2,788 (20) 719 (21) 264 (18) 37 (7)
35þ kg/m2 722 (5) 258 (7) 58 (4) 5 (1)
Diabetes 3,391 (24) 860 (25) 423 (29) 133 (27) 0.001
Creatinine, mg/dl 1.2 (1.0–1.5) 1.2 (1.0–1.6) 1.1 (0.9–1.4) 1.1 (0.9–1.4) <0.001
Dialysis 210 (2) 73 (2) 32 (2) 13 (3) 0.01
Wait-list time, days 79 (24–213) 71 (24–195) 57 (20–163) 44 (13–134) <0.001
IABP 772 (5) 188 (5) 74 (5) 38 (8) 0.2
Mechanical circulatory
support
ECMO 77 (0.5) 13 (0.4) 2 (0.1) 3 (0.6) 0.1
VAD 3,966 (33) 1,064 (35) 342 (27) 127 (29) <0.001
Mean PAP 27 (20–35) 30 (23–37) 29 (22–36) 27 (20–35) <0.001
Mean PCWP 18 (12–24) 19 (12–26) 20 (13–26) 17 (12–25) <0.001
Insurance <0.001
Private 8,819 (62) 1,599 (46) 592 (41) 313 (63)
Medicaid 1,157 (8) 701 (20) 360 (25) 57 (11)
Medicare 3,684 (26) 986 (28) 381 (26) 79 (16)
Other gov’t 420 (3) 119 (3) 93 (6) 15 (3)
Other 188 (1) 69 (2) 35 (2) 36 (7)
Education <0.001
College or graduate
degree
3,256 (23) 468 (14) 153 (11) 183 (37)
GED or <HS 5,257 (37) 1,560 (45) 763 (52) 108 (22)
Some college 2,969 (21) 826 (24) 237 (16) 95 (19)
Prior pregnancies <0.001
0 11,479 (90) 2,338 (83) 1,116 (87) 410 (91)
1 212 (2) 114 (4) 37 (3) 4 (1)
2 368 (3) 115 (4) 42 (3) 17 (4)
3þ 458 (4) 168 (6) 70 (5) 15 (3)
Prior transfusion 2,335 (29) 316 (19) 165 (22) 67 (30) <0.001
Allograft ischemic time,
h
3.2 (2.5–3.9) 3.1 (2.4–3.8) 3.1 (2.4–3.9) 3.3 (2.5–4.0) <0.001
Donor age, yrs 29 (21–42) 29 (21–41) 27 (20–39) 27 (20–41) <0.001
Values are median (interquartile range) or n (%) of patients.
BMI ¼ body mass index; ECMO ¼ extracorporeal membrane oxygenation; GED ¼ graduate equivalent degree; HS ¼ high school; HT ¼ heart
transplantation; IABP ¼ intra-aortic balloon pump; MCS ¼ mechanical circulatory support; PAP ¼ pulmonary artery pressure at time of transplant;
PCWP ¼ pulmonary capillary wedge pressure at time of transplant; VAD ¼ ventricular assist device.
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2310a higher proportion of female recipients than did the other
3 racial/ethnic groups. Hispanic recipients were more likely
to have O blood type. Hispanic and Asian recipients weremore likely to have a history of diabetes and less likely to
have received a ventricular assist device (VAD). Black and
Hispanic recipients were more likely to have had Medicaid
Table 2 PRA and HLA Match Levels by Race/Ethnicity
White
(n ¼ 14,269)
Black
(n ¼ 3,474)
Hispanic
(n ¼ 1,461)
Asian
(n ¼ 500) p Value
Most recent PRA, % 0 (0–0) 0 (0–3)*y 0 (0–1) 0 (0–2) <0.001
Peak PRA, % 2 (0–20) 7 (0–37)*yz 2 (0–18) 5 (0–25)x <0.001
Sensitization 2,761 (19) 936 (27) 273 (19) 107 (21) <0.001
HLA mismatch loci 5 (4–5) 5 (4–6)*y 5 (4–5)*k 5 (4–6)*{ <0.001
Values are median (interquartile range) or n (%) of patients. *p  0.001 versus white. yp < 0.001 versus Hispanic. zp ¼ 0.03 versus Asian. xp ¼ 0.02 versus white. kp < 0.001 versus Asian. {p ¼ 0.02 versus
Hispanic.
HLA ¼ human leukocyte antigen; PRA ¼ panel reactive antibody. Sensitization denotes PRA 10%
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2311or Medicare as their primary payer and had a lower mean
level of education. Black and Hispanic recipients were more
likely to have had multiple pregnancies but were less likely to
have had prior blood transfusions. Allograft ischemic time
was shorter in black and Hispanic recipients, and donor age
was younger in Hispanic and Asian recipients.
PRA and HLA mismatch. Table 2 summarizes the
median values for the most recent and peak PRA, and the
frequency of HLA mismatch by race/ethnicity. Black
recipients had higher peak PRA than did the other 3
groups, and had higher most recent PRA values than did
the white and Hispanic recipients. Compared with whites,
all race/ethnic minorities had a higher level of HLA
mismatch.
Inﬂuence of PRA on wait-list times. Overall, the median
time on the wait-list was longest in whites and shortest in
Asians (Table 1). Sensitized recipients had longer median
wait times than did nonsensitized recipients (111 [IQR: 37
to 277] days vs. 66 [IQR: 21 to 186] days; p < 0.001).
Figure 1 illustrates the cumulative proportion of patients
who underwent HT by 180 days according to sensitizationFigure 1 Stratiﬁcation of Heart Transplant Recipients
Proportion of patients receiving heart transplant, stratiﬁed by (A) level of sensitization an
Unadjusted Kaplan-Meier estimates of 1 – Survival, with a primary outcome of proportion(Fig. 1A) and according to race and sensitization (Fig. 1B).
After adjusting for BMI, blood type, sensitization, presence
of VAD at transplantation, and region, both black and
Hispanic race/ethnicity (beta: 0.046; p < 0.001) and peak
PRA (beta: 0.146; p < 0.001) were independently associated
with longer wait times.
Inﬂuence of PRA and HLA mismatch on treatment for
rejection post-transplantation. Overall, the likelihood of
being treated for rejection within 1 year of HT was 20.8%
among all HT recipients and was similar between sensitized
and nonsensitized patients (20.4% vs. 20.9%; p ¼ 0.4). In
nonsensitized patients, black recipients were the group
most likely to be treated for rejection within 1 year of HT
(564 [31%] vs. 2,405 [27%], 237 [27%], and 59 [22%] in
whites, Hispanics, and Asians, respectively; p ¼ 0.005).
In sensitized patients, however, there was no statistical
difference in the likelihood of being treated for rejection
based on race/ethnicity (202 [31%] vs. 562 [28%], 47 [25%],
and 19 [25%]; p ¼ 0.2).
The likelihood of being treated for rejection within 1 year
of HT was higher in HT recipients with HLA mismatchd (B) race/ethnicity and level of sensitization, and panel reactive antibody (PRA).
of patients receiving transplant at 180 days.
Table 3
Univariate Predictors of Graft Failure (Cox Regression)
(n ¼ 5,314)
Variable
Graft Failure
HR (95% CI) p Value
Age group <0.001
18–39 yrs Reference
40–59 yrs 0.79 (0.74–0.85)*
60–69 yrs 0.96 (0.88–1.03)
70þ yrs 1.17 (0.95–1.44)
Female 1.11 (1.05–1.12) <0.001
Race/ethnicity <0.001
White Reference
Black 1.39 (1.30–1.48)*
Hispanic 1.12 (1.01–1.24)
Asian 0.93 (0.77–1.13)
Education <0.001
College or graduate degree Reference
GED or <HS 1.28 (1.19–1.39)*
Some college 1.08 (0.99–1.18)
Insurance <0.001
Private Reference
Medicaid 1.33 (1.23–1.45)*
Medicare 1.26 (1.18–1.34)*
Other gov’t 0.97 (0.83–1.13)
Prior transfusion 1.08 (1.01–1.16) 0.035
Prior pregnancies <0.001
0 Reference
1 1.19 (1.01–1.40)
2 1.13 (0.99–1.30)
3þ 1.27 (1.13–1.42)*
LVAD 1.15 (1.08–1.22) <0.001
Renal dysfunction (creatinine >2 mg/dl) 1.65 (1.51–1.80) <0.001
BMI stratum 0.001
<25 kg/m2 Reference
25–29 kg/m2 0.99 (0.93–1.05)
30–35 kg/m2 1.07 (0.99–1.16)
35þ kg/m2 1.23 (1.09–1.39)*
Sensitization (PRA 10%) 1.17 (1.10–1.25) <0.001
HLA mismatch 5 loci 1.08 (1.02–1.15) 0.007
Donor age, yrs 1.01 (1.01–1.014) <0.001
Ischemic time, h 1.09 (1.06–1.11) <0.001
Other variables that were tested but were not signiﬁcant included ABO blood group. *p  0.001.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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2312at 5 loci compared with those with less HLA mismatch
(63% vs. 58%; p < 0.001). In recipients with HLA
mismatch at 5 loci, Asian recipients were the least likely to
be treated for rejection within 1 year of HT (40 [20%] vs.
1,562 [29%], 183 [31%], and 491 [32%] in whites,
Hispanics, and blacks, respectively; p ¼ 0.001). In recipients
with HLA mismatch at <5 loci, however, there was no
statistical difference in the likelihood of being treated for
rejection between racial/ethnic groups.
Post-transplantation graft failure. Thirty-three patients
(0.2%) died during the transplantation procedure. The
median follow-up time in the recipients who survived
transplantation was 1,207 days (IQR: 373 to 2,364 days),
with 580 recipients (3%) deemed lost to follow-up. Overall,
5,314 recipients (26%) were reported to have experienced
graft failure during the study period. Of these, 5,098 re-
cipients (96%) died and 200 (3.7%) underwent repeat
transplantation; 16 recipients (0.3%) did not have further
information regarding the outcome of graft failure. The
most commonly reported causes of death included cardio-
vascular (16%), infection (15%), multiorgan failure (9%),
malignancy (8%), and rejection (8%). The most commonly
reported causes of graft failure were rejection (52%) and
primary graft failure (35%). Univariate predictors of graft
failure included age, female sex, black and Hispanic race/
ethnicity, education, insurance type, prior transfusion, prior
pregnancies, presence of VAD, renal dysfunction, BMI,
sensitization, HLA mismatch, donor age, and allograft
ischemic time (Table 3).
Overall rates of graft survival at 1 and 5 years in whites,
blacks, Hispanics, and Asians were 85% and 72%, 79%
and 63%, 84% and 67%, and 85% and 75%, respectively.
Black HT recipients were more likely to experience graft
failure than were Hispanic, white, and Asian recipients
(31% vs. 27%, 26%, and 21%; p < 0.001). There was a trend
toward a shorter median time to graft failure in Asians than
in blacks, Hispanics, and whites (411 [IQR: 46 to 1,081]
days vs. 509 [IQR: 113 to 1,371], 584 [IQR: 83 to 1,530],
and 576 [IQR: 64 to 1,760] days; p ¼ 0.065).
Figure 2 illustrates the probability of graft survival on the
basis of race/ethnicity and presence of sensitization. Sensi-
tized blacks had the lowest graft survival, whereas non-
sensitized Asians had the highest graft survival. In
multivariate analysis adjusted for age, sex, BMI, insurance
status, level of education, prior transfusion, prior pregnan-
cies, HLA mismatch, renal function, presence of VAD, and
donor age and allograft ischemic time, black race (adjusted
HR: 1.3; 95% CI: 1.2 to 1.5), Hispanic ethnicity
(adjusted HR: 1.2; 95% CI: 1.0 to 1.4), and sensitization
(adjusted HR: 1.2; 95% CI: 1.1 to 1.4) remained signiﬁcant
predictors of higher probability of graft failure (Table 4).
Formal testing for interaction of race with sensitization
was not signiﬁcant (p ¼ 0.5). Other multivariate predic-
tors of graft failure included having Medicaid/Medicare
insurance, renal dysfunction, HLA mismatch, older donor
age, and longer ischemic time.Discussion
In this study, we report that: 1) black and Hispanic
patients continue to have higher rates of graft failure
than did other racial/ethnic groups, and the risk for graft
failure was highest in blacks with high PRA levels; 2) HLA
mismatch was related to graft failure in our sample, and
racial/ethnic minorities were more likely to have HLA
mismatch compared with white HT recipients; and 3)
there appeared to have been a trend toward decreased risk
of rejection requiring treatment and graft failure in Asian
HT recipients despite higher PRA levels and more HLA
mismatch compared with their white counterparts.
Our ﬁndings support and extend previous data showing
higher mortality in black and Hispanic HT recipients. Prior
Table 4
Multivariate Predictors of Graft Failure
(Cox Regression) (n ¼ 5,314)
Variable
Graft Failure,
HR (95% CI) p Value
Race/ethnicity
White Reference d
Black 1.3 (1.2–1.5) <0.001
Hispanic 1.2 (1.0–1.5) 0.035
Asian 1.2 (0.8–1.8) 0.3
Sensitization (PRA 10%) 1.2 (1.1–1.4) 0.004
Age group
18–39 yrs Reference d
40–59 yrs 0.8 (0.7–0.9) 0.007
60–69 yrs 1.0 (0.8–1.1) 0.3
70þ yrs 1.0 (0.6–1.6) 0.9
Insurance
Private Reference d
Medicaid 1.2 (1.0–1.4) 0.03
Medicare 1.2 (1.1–1.3) 0.03
Other government 1.1 (0.8–1.4) 0.5
Prior transfusion 1.1 (1.0–1.3) 0.02
Renal dysfunction (creatinine >2 mg/dl) 1.7 (1.5–2.0) <0.001
HLA mismatch 5 loci 1.1 (1.0–1.3) 0.01
Donor age, yrs 1.01 (1.0–1.01) <0.001
Ischemic time, h 1.1 (1.0–1.1) 0.01
Other variables that were included in the model but were not signiﬁcant included sex, BMI, previous
pregnancies, education, and VAD at transplantation.
Abbreviations as in Tables 1 to 3.
Figure 2 Graft Failure in Heart Transplant Recipients
Kaplan-Meier curve showing the primary outcome, graft failure, stratiﬁed by
race/ethnicity and panel reactive antibody (PRA) level. Unadjusted Kaplan-Meier
estimates showing the primary outcome, graft failure.
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2313large analyses from the OPTN database have consistently
shown worse outcomes in blacks, including higher risks for
rejection, hospitalization, and death, even after adjustment
for the higher clinical risk proﬁle often seen pre-
transplantation in black patients (1,4,8). Other investiga-
tors have reported higher PRA levels in black patients
(9,10); however, there are little data to date reported on
PRA levels in HT recipients of Hispanic ethnicity.
Although the black patients in our cohort had higher PRA
levels, the differences in the degree of sensitization did
not fully account for the differences in outcomes; black
race remained a signiﬁcant predictor of graft failure after
adjustment for recipient, transplant, and SES factors.
Immunologic mechanisms have been implicated as a cause
of the higher rates of graft failure seen in minority transplant
recipients. Prior studies have suggested heightened immu-
nologic responsiveness, as well as differences in immuno-
suppressant drug metabolism (11) and responsiveness (12),
as contributors to differential responses to allograft trans-
plantation in minority racial/ethnic groups. Additionally,
genetic variations put blacks and Hispanics at increased risk
for receipt of grafts poorly matched for HLA antigens
compared with white transplant recipients (5,13,14).
Unfortunately, the complexity of the genetic composition of
HLA antigens and the relative paucity of organ donors of
minority background make it exceptionally difﬁcult to ach-
ieve equitable matching in racial/ethnic minorities compared
with whites in the United States, particularly among blacks.
Furthermore, the use of HLA matching for solid-organ
transplantation remains highly controversial in part becausethe risk for mismatch is high in all groups irrespective of race
due to the extensive polymorphism of the HLA system, and
the average number of antigens mismatched does not vary
greatly among different racial/ethnic groups (14). There are
conﬂicting data regarding HLA matching on allograft
survival, as some studies have suggested that HLA mismatch
number did not affect time to ﬁrst rejection or rejection
frequency among black patients (15,16), whereas others have
found HLA mismatch related to worse outcomes (5). Our
data suggest that HLA mismatch did indeed increase the
likelihood of graft failure over the study period. More
investigation is needed to clarify the effects of HLA
matching in HT.
Interestingly, the higher levels of PRA and HLA
mismatch seen in Asian HT recipients in our cohort did not
appear to affect a higher risk for graft failure. Prior data have
shown lower rates of sensitization in Asians compared with
other racial/ethnic groups (17). In our cohort, Asians were
the second-most sensitized group, likely due to a fairly high
prevalence of prior blood transfusions. Other studies have
also shown HT recipients of Asian race to have signiﬁcantly
reduced rates of rejection compared with other racial/ethnic
groups (3,18). Data from kidney transplant recipients have
also shown superior graft survival in Asian recipients, and
the authors speculate that the reason for this could be more
favorable pre-transplantation characteristics, such as a lower
BMI; fewer comorbidities; and higher levels of education,
which might give rise to better compliance and, hence, better
outcomes post-transplantation (19). A prior report from
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2314a single-center experience has also shown superior graft
survival in Asian HT recipients (3). To the best of our
knowledge, ours is the largest series in HT recipients in the
United States conﬁrming the lower risk for rejection and
superior graft survival in Asians, despite higher degrees of
sensitization and HLA mismatch. The mechanisms for this
protective effect are unclear; however, the ﬁndings warrant
further investigation.
Other mechanisms certainly contribute to worse outcomes
in racial/ethnic minorities, including SES. Black and
Hispanic HT recipients have been shown in prior studies to
be less educated and more likely to have Medicaid as their
primary payer (4,6), and these differences were supported in
this cohort. However, adjusting for education and insurance
status did not appear to eliminate the differences in graft
survival in our analysis. A prior report in 525 HT recipients
showed that low SES and nonwhite ethnicity were both
associated with risk for graft loss and risk for rejection
episodes (4). Similar to our ﬁndings, that study showed
that low SES modestly lowered the impact of nonwhite
race on graft loss, but that both SES and race appeared
to be of independent predictive value. Those authors
speculated that SES factors might amplify the effects of
biological differences in racial groups on outcomes. Certainly
there could be other SES factors or confounders that are
unaccounted for in our model; however, our data strongly
suggest that the observed differences are not explained by
SES alone.
Prior data suggest that comprehensive care may abrogate
many of the racial/ethnic disparities observed in other
cohorts. Despite worse pre-transplantation hemodynamic
proﬁle, higher pre-transplantation PRA levels, and more
post-transplantation hospitalizations and episodes of rejec-
tion in black patients, Pamboukian et al. (20) reported no
difference in 5-year survival in their series. In this series,
black patients had more intense utilization of both outpa-
tient and inpatient resources. These authors concluded that
aggressive surveillance and medical intervention may negate
some of the effects of a greater risk for rejection in black
patients.
Study limitations. There have been signiﬁcant advances
in both HLA and PRA technology during the current era
(21,22) that may have affected the reported results. For
instance, most centers have evolved from the use of
complement-dependent cytotoxicity testing to PRA assays
based on ﬂow cytometry. However, we cannot fully
account for how the use of different assays may have
affected our ﬁndings. Furthermore, even with current
methods, the degree of sensitization represented by PRA
can be highly variable and inconsistent because the value of
PRA depends both on the panel composition and the
technique used for antibody detection. Because the percent
reactivity of the panel depends on the composition of the
donor pool, it is possible that donor pools are more likely
to have a substantial number of white donors, leading to
higher panel reactivity in racial/ethnic minorities. We alsodid not have information on calculated PRA, which
corresponds to the frequency of unacceptable antigens in
a large population of HLA-typed United Network of
Organ Sharing donors, and more accurately assesses the
likelihood of a sensitized patient to be compatible with
a deceased donor (22). Next, we did not adjust for center
volume, which may affect post-transplantation outcomes.
Prior studies have shown that black and Hispanic patients
are more likely to be listed at low-volume centers;
however, adjusted analyses have shown that center volume
does not account for racial/ethnic differences in post-
transplantation mortality (6). Finally, race/ethnicity is by
self-report, and in particular it is unclear whether patients
who were identiﬁed as Asian were of South or East Asian
descent, as the cardiovascular proﬁles often differ in these
groups.Conclusions
Black and Hispanic patients are at a higher risk for graft
failure post-transplantation, with sensitized blacks having
the poorest long-term outcomes. Despite substantial
improvements during the current era in the application of
HLA technology, clear disparities exist that put certain
racial/ethnic minorities at higher risk for allograft failure
independent of differences in SES. These gaps in post-
transplantation outcomes warrant further investigation.
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